Key result
Pharmacological depletion of PD1 prior to reperfused acute myocardial infarction in mice did not alter the area of infarction but led to increased numbers of CD8+ T cells.
Why the study?
Understanding the relevance of cardiac PD1 signaling may provide new insights into inflammatory events under baseline conditions and disease.
Does PD1 deficiency or depletion modify cardiac immunity and infarct size in baseline conditions and reperfused acute myocardial infarction?
Does PD1 deficiency or depletion modify cardiac immunity and infarct size in baseline conditions and reperfused acute myocardial infarction?
Answers are grounded in this paper and cite their sources.
PD1/PDL1 signaling plays a significant role in cardiac immunity, highlighting potential risks for adverse outcomes from acute myocardial infarction in patients receiving immune checkpoint inhibitors.
The programmed cell death protein 1 (PD1) immune checkpoint prevents inflammatory tissue damage by inhibiting immune reactions. Understanding the relevance of cardiac PD1 signaling may provide new insights into the inflammatory events under baseline conditions and disease. Here, we demonstrate distinct immunological changes upon PD1 deficiency in healthy hearts and during reperfused acute myocardial infarction (repAMI). In PD1-deficient mice, upregulated inflammatory cytokines were identified under baseline conditions including cardiac interleukins and extracellular signal-related kinase 1/2 (ERK1/2). A murine in vivo repAMI model to determine inflammatory changes in the early phase showed downregulation of the ligand PDL1, paralleled by an endothelial injury, indicated by loss of the CD31 signal. Immunofluorescence imaging showed decreased PDL1 expression specifically in the infarct zone, highlighting an involvement in PDL1 in myocardial injury response. Pharmacological depletion of PD1 prior to repAMI did not alter the area of infarction but led to increased numbers of CD8+ T cells in treated mice. We conclude that PD1/PDL1 signaling plays a significant role in healthy hearts and repAMI, emphasizing the relevance of adaptive immunity during myocardial injury. The findings highlight the risk for adverse outcomes from acute myocardial infarction in the growing group of patients receiving immune checkpoint inhibitor therapy.
No takes yet. Share an insight, caveat, or question.
Michel et al. (2022) studied Reperfused acute myocardial infarction (repAMI). PD1 deficiency and pharmacological depletion of PD1 vs. Baseline conditions / untreated mice was evaluated on Area of infarction and inflammatory changes (CD8+ T cells). Pharmacological depletion of PD1 prior to reperfused acute myocardial infarction in mice did not alter the area of infarction but led to increased numbers of CD8+ T cells.
Synapse has enriched 10 related papers. Consider them for comparative context: